ABOUT / COMPANY INFORMATION

Haematex Milestone Achievements

2022

New website and logo launched
Global product manager appointed
International Haematology Consultant appointed
DOAC-Stop™, SACT-II and HRRS being transitioned from CE to EUDAMED

2021

Marie-Curie fellow Dr Manita Dangol appointed
International distribution network expanded into Africa  

2020

Contribution to COVID-19 effort - hand sanitiser distributed
Inhibitor Dots developed

2019

DOAC-Stop™ manufactured as IVD and listed on ARTG

2018

DOAC-Stop™ CE marked for European distribution

2017

DOAC-Stop™ in development

2015

HRRS - manufactured as IVD and listed on the ARTG

2014

DOAC Test Developed.
Bioporto Diagnostics distribution agreement.

2012

Ready for use dRVVT reagents developed.

2011

HRRS and SACT-II CE marked for European distribution

2008

Collagen Binding ELISA developed.
Hyphen-BioMed distribution agreement.
HRRS developed.

2007

APTT first commercialised for South American market

2006

Patented XACT test for procoagulant phospholipid.

2005

Developed APTT reagents from dry powders

2004

Haematex Research Pty Ltd established

Image: Dr Thomas Exner at work

Company Profile

Tens of millions of people world-wide have been affected by the impact of thrombosis and hemorrhage. Vital clinical decisions can affect treatment outcomes and indeed life itself. Inspired by founder Dr. Thomas Exner’s passion to develop a screening test for early detection of thrombotic events, Haematex was established to provide niche products and services in the coagulation diagnostics industry.

The now widely used dRVT and newer DOAC-Stop™ first emerged from our Sydney based R&D efforts. These globally embraced products encourage us to keep innovating. We live for cultivating the culture of thinking “outside the box” where we grow new concepts which become the core of new product development.  

To complement your testing needs, our existing product range includes bulk powder concentrates, liquid-stable reagents, sample pre-treatment agents, all of which are distributed globally. You may also find benefit from our custom-made reagents tailored to your specific requirements. Our quality IVD products supplied for the Australian market are registered on the Australian Register of Therapeutic Goods (ARTG). We also have a range of selected CE marked products for European distribution. Due to the nature of some of our products being based on Russell Viper venom, we comply with all CITES import and export regulations and all relevant permits are acquired accordingly. We are also compliant with all BICON regulations.  

You will also find our range of high-quality products which we distribute for Hyphen Bio-Med and Bioporto Diagnostics an asset to your laboratory.  

Got a question for us?

Use this form to send us a message:

All fields are required.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.